Alembic Pharmaceuticals (APLLTD) Stock Overview
An integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
APLLTD Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alembic Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹797.05 |
| 52 Week High | ₹1,002.00 |
| 52 Week Low | ₹635.80 |
| Beta | 0.37 |
| 1 Month Change | -2.60% |
| 3 Month Change | 5.57% |
| 1 Year Change | -16.89% |
| 3 Year Change | 2.13% |
| 5 Year Change | 1.79% |
| Change since IPO | 1,569.21% |
Recent News & Updates
Recent updates
Narrative Update • Jun 24
APLLTD: US Approvals And Exclusivity Opportunities Will Drive Upside
The analyst fair value estimate for Alembic Pharmaceuticals has shifted from ₹939.90 to ₹907.20, reflecting updated assumptions on revenue growth, profit margins, discount rate and future P/E expectations according to analysts. What's in the News Alembic Pharmaceuticals received tentative USFDA approval for Binimetinib Tablets 45 mg, a kinase inhibitor used with encorafenib for certain melanoma and metastatic non small cell lung cancer patients.
Narrative Update • Jun 10
APLLTD: USFDA Approvals For Key Therapies Will Drive Future Upside
Analysts have revised their fair value estimate for Alembic Pharmaceuticals to ₹1,132 from ₹1,275, reflecting updated assumptions around slightly higher revenue growth, a lower discount rate, a lower profit margin, and a reduced future P/E multiple. What's in the News Alembic Pharmaceuticals received final USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg, which are therapeutically equivalent to Farxiga Tablets of AstraZeneca and qualify for 180 days of shared generic drug exclusivity, with an estimated market size of US$10.487b for the twelve months ending December 2025 (source: company announcement).
Narrative Update • May 27
APLLTD: US Generics Pipeline And Leadership Transition Will Shape Balanced Future Prospects
The analyst fair value estimate for Alembic Pharmaceuticals has been revised from ₹845.0 to ₹715.0. Analysts attribute this change to updated assumptions that combine slightly lower revenue growth and a lower future P/E with a higher projected profit margin. What's in the News Alembic received USFDA tentative approval for Darolutamide Tablets, 300 mg, a generic version of Nubeqa used in several prostate cancer indications, with an estimated market size of US$3.155b for the twelve months ending March 2026 according to IQVIA (company announcement).Analysis Article • May 18
The Alembic Pharmaceuticals Limited (NSE:APLLTD) Annual Results Are Out And Analysts Have Published New Forecasts
Alembic Pharmaceuticals Limited ( NSE:APLLTD ) came out with its full-year results last week, and we wanted to see how...Narrative Update • Apr 23
APLLTD: Expanding US Generic Portfolio And First Branded Launch Will Drive Upside
Analysts now place Alembic Pharmaceuticals' fair value at ₹939.9, about ₹10 lower than the prior ₹949.9 view. This reflects updated assumptions around slightly different revenue growth, profit margin, and future P/E inputs.Narrative Update • Apr 08
APLLTD: US Approvals And First Branded Launch Will Support Upside Potential
Analysts have trimmed their price target on Alembic Pharmaceuticals from ₹1,056.64 to ₹949.90, citing updated assumptions for the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Alembic received final USFDA approval for a supplemental Abbreviated New Drug Application for Paroxetine Extended Release Tablets, 12.5 mg, which are therapeutically equivalent to Paxil CR Tablets.Narrative Update • Mar 25
APLLTD: Expanding US Branded And Generic Portfolio Will Support Long Term Upside
Analysts have maintained Alembic Pharmaceuticals' price target at ₹845, reflecting only minor tweaks to revenue growth, profit margin and future P/E assumptions, rather than a shift in their overall view of the stock. What's in the News Alembic Therapeutics LLC, a step down wholly owned subsidiary, reported its first prescription based sale in the US after the commercial launch of Pivya (pivmecillinam) tablets for uncomplicated urinary tract infections in adult women.Narrative Update • Mar 09
APLLTD: Recent US Approvals Will Support A Constructive Long Term Outlook
Analysts have kept their fair value estimate for Alembic Pharmaceuticals steady at ₹845, citing only modest tweaks to revenue growth, profit margin and future P/E assumptions that did not justify a change in the price target. What's in the News Alembic received final US FDA approval for Lamotrigine Orally Disintegrating Tablets in multiple strengths, which are therapeutically equivalent to Lamictal ODT and have an estimated US market size of US$27 million for the twelve months ending December 2025 (IQVIA).Narrative Update • Feb 23
APLLTD: US Approvals And Margin Profile Will Guide A Steady Outlook
Analysts have maintained their fair value estimate for Alembic Pharmaceuticals at ₹845. They have made modest adjustments to assumptions around revenue growth, profit margin, and future P/E to reflect updated views on the company’s earnings profile, without changing the overall price target.Narrative Update • Feb 09
APLLTD: US Approvals And Margin Assumptions Will Shape A Balanced Outlook
Alembic Pharmaceuticals' analyst fair value estimate has shifted from ₹900.00 to ₹845.00 as analysts adjust their expectations for revenue growth, profit margins and future P/E assumptions in light of the latest research inputs. What's in the News Alembic received final USFDA approval for Difluprednate Ophthalmic Emulsion, 0.05%, a generic version of Durezol, for treating inflammation and pain after ocular surgery and endogenous anterior uveitis, taking its cumulative USFDA ANDA approvals to 233 (company announcement).Analysis Article • Feb 08
Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
The quarterly results for Alembic Pharmaceuticals Limited ( NSE:APLLTD ) were released last week, making it a good time...Analysis Article • Jan 09
We Think Alembic Pharmaceuticals (NSE:APLLTD) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Nov 12
Why We're Not Concerned About Alembic Pharmaceuticals Limited's (NSE:APLLTD) Share Price
With a median price-to-earnings (or "P/E") ratio of close to 27x in India, you could be forgiven for feeling...Narrative Update • Sep 05
US Product Launches And India Execution Will Expand Reach
As both net profit margin and revenue growth forecasts for Alembic Pharmaceuticals remain stable, the consensus analyst price target is unchanged at ₹1057. What's in the News Alembic Pharmaceuticals received USFDA final approval for Macitentan Tablets, 10 mg, a generic of Opsumit, targeting a USD 1,180 million market.Analysis Article • Aug 08
Analysts Are Updating Their Alembic Pharmaceuticals Limited (NSE:APLLTD) Estimates After Its First-Quarter Results
Shareholders might have noticed that Alembic Pharmaceuticals Limited ( NSE:APLLTD ) filed its quarterly result this...Analysis Article • Jul 11
Alembic Pharmaceuticals Limited's (NSE:APLLTD) P/E Still Appears To Be Reasonable
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 29x, you may consider...Analysis Article • May 11
Here's What Analysts Are Forecasting For Alembic Pharmaceuticals Limited (NSE:APLLTD) After Its Annual Results
As you might know, Alembic Pharmaceuticals Limited ( NSE:APLLTD ) just kicked off its latest yearly results with some...Analysis Article • Mar 31
What Alembic Pharmaceuticals Limited's (NSE:APLLTD) 25% Share Price Gain Is Not Telling You
Those holding Alembic Pharmaceuticals Limited ( NSE:APLLTD ) shares would be relieved that the share price has...
New Narrative • Feb 09
Future US Launches And GLP-1 Investments Will Strengthen Market Position
Aggressive U.S. product launch strategy and peptide investments to counter price erosion and drive future high-margin revenue growth.Analysis Article • Feb 06
Alembic Pharmaceuticals Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for Alembic Pharmaceuticals Limited ( NSE:APLLTD ), which a week ago released some...Analysis Article • Jan 11
Why We're Not Concerned About Alembic Pharmaceuticals Limited's (NSE:APLLTD) Share Price
It's not a stretch to say that Alembic Pharmaceuticals Limited's ( NSE:APLLTD ) price-to-earnings (or "P/E") ratio of...Analysis Article • Nov 10
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
Alembic Pharmaceuticals Limited ( NSE:APLLTD ) just released its latest quarterly report and things are not looking...Analysis Article • Sep 25
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Key Insights The projected fair value for Alembic Pharmaceuticals is ₹963 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Sep 03
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Aug 13
Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
The analysts might have been a bit too bullish on Alembic Pharmaceuticals Limited ( NSE:APLLTD ), given that the...Analysis Article • Jul 20
Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Alembic Pharmaceuticals Limited ( NSE:APLLTD ) shares have had a really impressive month, gaining 25% after a shaky...Analysis Article • Jun 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • May 11
Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
Key Insights The projected fair value for Alembic Pharmaceuticals is ₹775 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Feb 08
Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Alembic Pharmaceuticals Limited ( NSE:APLLTD ) last week reported its latest third-quarter results, which makes it a...Analysis Article • Jan 21
Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Alembic Pharmaceuticals Limited ( NSE:APLLTD ) shareholders would be excited to see that the share price has had a...Shareholder Returns
| APLLTD | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.07% | 2.3% | 2.0% |
| 1Y | -16.9% | 16.0% | 3.6% |
Return vs Industry: APLLTD underperformed the Indian Pharmaceuticals industry which returned 16% over the past year.
Return vs Market: APLLTD underperformed the Indian Market which returned 3.6% over the past year.
Price Volatility
| APLLTD volatility | |
|---|---|
| APLLTD Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.7% |
Stable Share Price: APLLTD has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: APLLTD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1907 | 17,244 | n/a | alembicpharmaceuticals.com |
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products.
Alembic Pharmaceuticals Limited Fundamentals Summary
| APLLTD fundamental statistics | |
|---|---|
| Market cap | ₹156.67b |
| Earnings (TTM) | ₹6.75b |
| Revenue (TTM) | ₹73.45b |
23.2x
P/E Ratio2.1x
P/S RatioIs APLLTD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLLTD income statement (TTM) | |
|---|---|
| Revenue | ₹73.45b |
| Cost of Revenue | ₹20.79b |
| Gross Profit | ₹52.66b |
| Other Expenses | ₹45.91b |
| Earnings | ₹6.75b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 04, 2026
| Earnings per share (EPS) | 34.33 |
| Gross Margin | 71.70% |
| Net Profit Margin | 9.19% |
| Debt/Equity Ratio | 24.0% |
How did APLLTD perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield35%
Payout RatioDoes APLLTD pay a reliable dividends?
See APLLTD dividend history and benchmarks| Alembic Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | Jul 29 2026 |
| Dividend Pay Date | Sep 04 2026 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 33 days |
Does APLLTD pay a reliable dividends?
See APLLTD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/01 20:48 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alembic Pharmaceuticals Limited is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| null null | Antique Stockbroking Ltd. |
| Harith Ahamed | Avendus Spark |